(Q38255001)

1 September 2017

1 reference

title

Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies (English)

1 reference

1 September 2017

1 reference

1 reference

5

David A Reardon

1 reference

1 September 2017

3

Patrick Y Wen

1 reference

1 September 2017

Kathryn M Field

1

1 reference

1 September 2017

Justin T Jordan

series ordinal

2

1 reference

1 September 2017

Mark A Rosenthal

series ordinal

4

1 reference

1 September 2017

language of work or name

English

0 references

publication date

26 September 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

121

1 reference

1 September 2017

issue

7

1 reference

1 September 2017

page(s)

997-1007

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

A comparison of treatment results for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Current status of antiangiogenic therapies for glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Platelet-derived growth factor (PDGF) and glial tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Angiogenesis in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Glioblastoma stem-like cells give rise to tumour endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Transdifferentiation of glioblastoma cells into vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab and daily temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

7 January 2021

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

7 January 2021

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

7 January 2021

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

7 January 2021

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

7 January 2021

Carboplatin and bevacizumab for recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

7 January 2021

FDA cancels approval for bevacizumab in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28935

7 January 2021

Identifiers

DOI

10.1002/CNCR.28935

1 reference

1 September 2017

1 reference